C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain anemic. Pegcetacoplan (APL‐2), a PEGylated C3 inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: de Castro, Carlos, Grossi, Federico, Weitz, Ilene Ceil, Maciejewski, Jaroslaw, Sharma, Vivek, Roman, Eloy, Brodsky, Robert A., Tan, Lisa, Di Casoli, Carl, El Mehdi, Delphine, Deschatelets, Pascal, Francois, Cedric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693064/
https://www.ncbi.nlm.nih.gov/pubmed/33464651
http://dx.doi.org/10.1002/ajh.25960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693064/
https://www.ncbi.nlm.nih.gov/pubmed/33464651
http://dx.doi.org/10.1002/ajh.25960

Ejemplares similares